2025

1. ASO Visual Abstract: Anatomical Versus Non-anatomical Liver Resection for Intrahepatic Cholangiocarcinoma: A Systematic Review and Patient-Level Meta-analysis

   Annals of surgical oncology, Vol. 32, Núm. 1, pp. 460-461

2. An MRI/PET PSMA-based phase I–II study of salvage high-dose-rate brachytherapy after surgery and radiotherapy

   BJU International

3. Association of [68Ga]Ga-PSMA-11 PET/CT Metrics with PSA Persistence Following Radical Prostatectomy in Patients with Intermediate- and High-Risk Prostate Cancer

   Diagnostics, Vol. 15, Núm. 3

4. Circulating microRNA panels in subjects with metabolic dysfunction-associated steatotic liver disease after following a 2-year dietary intervention

   Journal of Endocrinological Investigation, Vol. 48, Núm. 4, pp. 987-1003

5. Clinical and dosimetric considerations for yttrium-90 glass microspheres radioembolization of intrahepatic cholangiocarcinoma, metastatic colorectal carcinoma, and metastatic neuroendocrine carcinoma: recommendations from an international multidisciplinary working group

   European Journal of Nuclear Medicine and Molecular Imaging

6. Comparison of staging using [68Ga]Ga-PSMA-11 PET/CT and histopathological results in intermediate- and high-risk prostate cancer patients treated with radical prostatectomy and pelvic lymph node dissection

   Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 44, Núm. 2

7. DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy

   Journal of Viral Hepatitis, Vol. 32, Núm. 2

8. Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study

   Hepatology

9. Does the type of neoplasm influence the development of postoperative complications following distal pancreatectomy? A multicenter prospective snapshot study from the Spanish distal pancreatectomy project (SPANDISPAN)

   Asian Journal of Surgery, Vol. 48, Núm. 7, pp. 4137-4143

10. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

    The Lancet, Vol. 405, Núm. 10474, pp. 216-232

11. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

    Journal of Hepatology, Vol. 82, Núm. 2, pp. 315-374

12. Efficacy and safety of ovarian vein embolization with N-butyl-2 cyanoacrylate for pelvic venous disorder: Analysis of 100 cases

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 13, Núm. 5

13. Evolving epidemiology of HCC in Spain

    JHEP Reports, Vol. 7, Núm. 5

14. Expression landscape of epigenetic genes in human hepatocellular carcinoma

    Journal of Physiology and Biochemistry

15. Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial

    Journal of Patient-Reported Outcomes, Vol. 9, Núm. 1

16. Horseshoe kidney

    International Journal of Gynecological Cancer

17. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA Phase 3 randomized clinical trial

    Hepatology

18. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

    Journal of Hepatology, Vol. 82, Núm. 1, pp. 107-119

19. Intraductal oncocytic papillary neoplasm of the pancreas

    Gastroenterologia y Hepatologia, Vol. 48, Núm. 4

20. Laparoscopic left hemihepatectomy using the Arantius-first approach after 90Y transarterial radioembolization and immunotherapy in a cirrhotic patient

    The British journal of surgery, Vol. 112, Núm. 2